{"id":"bnt323-db-1303","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This bispecific antibody platform is designed to bridge tumor cells and immune cells, enhancing T-cell activation and cytotoxic killing. By targeting both a tumor-associated antigen and an immune checkpoint or activating receptor, the drug aims to overcome immune evasion and drive anti-tumor immunity. The exact targets and mechanism are proprietary to BioNTech's development program.","oneSentence":"BNT323/DB-1303 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to redirect immune responses against cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:47:23.261Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under clinical evaluation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":"Metastatic Breast Cancer","enrollment":541},{"nctId":"NCT06340568","phase":"PHASE3","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-06-10","conditions":"Endometrial Cancer","enrollment":480},{"nctId":"NCT05150691","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2022-01-31","conditions":"HER2-positive Advanced Solid Tumor","enrollment":796},{"nctId":"NCT06265428","phase":"PHASE3","title":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-29","conditions":"HER2-positive Breast Cancer","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["trastuzumab pamirtecan"],"phase":"phase_3","status":"active","brandName":"BNT323/DB-1303","genericName":"BNT323/DB-1303","companyName":"BioNTech SE","companyId":"biontech-se","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BNT323/DB-1303 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to redirect immune responses against cancer cells. Used for Solid tumors (specific indication under clinical evaluation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}